论文部分内容阅读
目的:系统评价非布索坦治疗痛风的疗效及安全性。方法:计算机检索PubMed、EMBASE、SCI、CBM、CNKI、VIP、万方数据库及Cochrane图书馆,手工补充检索;纳入非布索坦治疗痛风的随机对照试验(RCT);进行方法学质量评价和Meta分析。结果:共纳入3个RCT(受试者1985例),A级文献1篇,B级文献2篇。Meta分析结果显示:最后3月血清尿酸(SU)持续低于6.0mg/dl患者数、随访结束时SU低于6.0mg/dl患者数非布索坦组与对照组差异均有统计学意义;治疗相关不良事件发生数与安慰剂组差异无统计学意义,与别嘌呤组差异有统计学意义。结论:基于当前证据,非布索坦治疗痛风,能有效降低SU含量,减少治疗相关不良事件发生率。
Objective: To systematically evaluate the efficacy and safety of febuxostat in the treatment of gout. METHODS: Computer-assisted searches of PubMed, EMBASE, SCI, CBM, CNKI, VIP, Wanfang and Cochrane libraries were performed manually. Randomized controlled trials (RCTs) of gaboxetan for the treatment of gout were conducted. analysis. Results: A total of 3 RCTs (1985 subjects), 1 A-level literature and 2 B-level literature were enrolled. The results of Meta analysis showed that the serum uric acid (SU) persisted lower than 6.0mg / dl in the last 3 months, and the difference was statistically significant between the febuxostat group and the control group when SU was lower than 6.0mg / dl at the end of follow - up. The number of treatment-related adverse events was not statistically different from placebo group, and the difference was statistically significant compared with allopurine group. CONCLUSIONS: Based on current evidence, febuxostat for the treatment of gout can effectively reduce SU levels and reduce the incidence of treatment-related adverse events.